Sapporo Clinical Laboratory Inc. (TYO:9776)
1,952.00
-8.00 (-0.41%)
Feb 13, 2026, 2:58 PM JST
TYO:9776 Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Cash & Equivalents | 3,423 | 2,941 | 3,976 | 3,664 | 2,990 | 2,360 |
Cash & Short-Term Investments | 3,423 | 2,941 | 3,976 | 3,664 | 2,990 | 2,360 |
Cash Growth | -5.57% | -26.03% | 8.52% | 22.54% | 26.70% | -13.46% |
Receivables | 3,062 | 2,871 | 2,919 | 2,924 | 2,995 | 2,749 |
Inventory | 782 | 615 | 578 | 514 | 490 | 507 |
Other Current Assets | 186 | 209 | 223 | 208 | 754 | 296 |
Total Current Assets | 7,453 | 6,636 | 7,696 | 7,310 | 7,229 | 5,912 |
Property, Plant & Equipment | 8,673 | 8,905 | 8,191 | 8,449 | 8,127 | 7,757 |
Long-Term Investments | 779 | 665 | 554 | 525 | 569 | 638 |
Other Intangible Assets | 113 | 124 | 96 | 89 | 60 | 42 |
Long-Term Deferred Tax Assets | 82 | 119 | 142 | 146 | 162 | 161 |
Other Long-Term Assets | 1 | 1 | 1 | 2 | 2 | 1 |
Total Assets | 17,102 | 16,450 | 16,680 | 16,521 | 16,149 | 14,511 |
Accounts Payable | 2,685 | 2,153 | 2,235 | 2,179 | 2,258 | 2,293 |
Accrued Expenses | 30 | 119 | 124 | 125 | 120 | 115 |
Current Portion of Long-Term Debt | 135 | 133 | 135 | 133 | 133 | 133 |
Current Portion of Leases | 125 | 121 | 125 | 127 | 106 | 23 |
Current Income Taxes Payable | 267 | 383 | 417 | 393 | 419 | 362 |
Other Current Liabilities | 375 | 212 | 271 | 299 | 245 | 179 |
Total Current Liabilities | 3,617 | 3,121 | 3,307 | 3,256 | 3,281 | 3,105 |
Long-Term Debt | 1,230 | 1,331 | 1,464 | 1,598 | 1,732 | 1,866 |
Long-Term Leases | 285 | 346 | 472 | 569 | 610 | 80 |
Pension & Post-Retirement Benefits | 105 | 97 | 91 | 87 | 82 | 71 |
Long-Term Deferred Tax Liabilities | 1 | 4 | 11 | 16 | - | - |
Other Long-Term Liabilities | 155 | 158 | 154 | 115 | 107 | 118 |
Total Liabilities | 5,393 | 5,057 | 5,499 | 5,641 | 5,812 | 5,240 |
Common Stock | 983 | 983 | 983 | 983 | 983 | 983 |
Additional Paid-In Capital | 1,015 | 1,015 | 1,015 | 1,015 | 1,015 | 1,015 |
Retained Earnings | 10,213 | 9,995 | 9,607 | 9,304 | 8,812 | 7,848 |
Treasury Stock | -947 | -947 | -757 | -757 | -728 | -633 |
Comprehensive Income & Other | 200 | 107 | 87 | 40 | 32 | 58 |
Total Common Equity | 11,464 | 11,153 | 10,935 | 10,585 | 10,114 | 9,271 |
Minority Interest | 245 | 240 | 246 | 295 | 223 | - |
Shareholders' Equity | 11,709 | 11,393 | 11,181 | 10,880 | 10,337 | 9,271 |
Total Liabilities & Equity | 17,102 | 16,450 | 16,680 | 16,521 | 16,149 | 14,511 |
Total Debt | 1,775 | 1,931 | 2,196 | 2,427 | 2,581 | 2,102 |
Net Cash (Debt) | 1,648 | 1,010 | 1,780 | 1,237 | 409 | 258 |
Net Cash Growth | 1.23% | -43.26% | 43.90% | 202.44% | 58.53% | -90.22% |
Net Cash Per Share | 528.41 | 322.89 | 534.53 | 371.03 | 120.08 | 75.37 |
Filing Date Shares Outstanding | 3.12 | 3.12 | 3.12 | 3.33 | 3.33 | 3.42 |
Total Common Shares Outstanding | 3.12 | 3.12 | 3.33 | 3.33 | 3.35 | 3.42 |
Working Capital | 3,836 | 3,515 | 4,389 | 4,054 | 3,948 | 2,807 |
Book Value Per Share | 3672.93 | 3574.98 | 3283.21 | 3178.13 | 3016.15 | 2708.22 |
Tangible Book Value | 11,351 | 11,029 | 10,839 | 10,496 | 10,054 | 9,229 |
Tangible Book Value Per Share | 3636.73 | 3535.23 | 3254.39 | 3151.40 | 2998.26 | 2695.95 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.